Streamex Corp., formerly known as BioSig Technologies, Inc., reported significant financial changes in its recent 10-K filing for the fiscal year ending December 31, 2025. The company, which transitioned from a medical device focus to a digital asset infrastructure model following its acquisition of Streamex Exchange, recorded no revenue for the year, a decrease from $40,000 in 2024. The net loss attributable to common stockholders surged to $462.8 million, compared to a loss of $10.5 million in the previous year. This dramatic increase was primarily driven by a non-cash loss of $389.7 million related to the change in fair value of a derivative liability associated with exchangeable shares prior to their reclassification to equity.
The acquisition of Streamex Exchange on May 28, 2025, marked a strategic pivot for the company, allowing it to enter the tokenized finance sector. The acquisition was valued at approximately $105.5 million, with the company issuing 109,070,039 exchangeable shares as part of the transaction. Following shareholder approval on November 4, 2025, these shares were reclassified to permanent equity, eliminating the associated derivative liability. The company also reported a substantial increase in general and administrative expenses, which rose to $67.5 million, largely due to stock-based compensation expenses that accounted for approximately $57.1 million.
Operationally, Streamex has not yet generated material revenue from its new digital asset platform, which is designed to facilitate the tokenization of real-world assets, starting with gold. The company launched its first product, GLDY, in early 2026, but as of the end of 2025, it remained in the development stage. The company’s workforce was minimal, with only six full-time employees and four consultants as of December 31, 2025. The company plans to expand its operations and product offerings, which will require additional investment in technology and compliance.
Looking ahead, Streamex Corp. anticipates continued operating losses and negative cash flows until its products achieve commercial success. The company has taken steps to strengthen its liquidity position, including a public offering that generated approximately $37.2 million in January 2026. However, the future financial performance will depend on various factors, including market conditions, regulatory developments, and the successful adoption of its tokenized products. The company is actively evaluating its strategic alternatives for its legacy subsidiaries, ViralClear Pharmaceuticals and BioSig AI Sciences, which are currently dormant or on hold.
About BioSig Technologies, Inc.
BioSig Technologies, Inc. develops advanced medical device technology focused on electrophysiology (EP) with its PURE EP™ Platform, which enhances real-time cardiac signal acquisition and analysis during catheter ablation of complex arrhythmias like atrial fibrillation and ventricular tachycardia. Serving electrophysiologists and EP labs, BioSig’s platform improves signal clarity and procedural precision, aiming to optimize ablation outcomes through proprietary hardware and software integrated into existing clinical workflows.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.